221050-71-1

Basic information

• Product Name: 7-Isoquinolinecarboxylicacid,1-amino-(9CI)
• Synonyms: 7-Isoquinolinecarboxylicacid,1-amino-(9CI);1-aminoisoquinoline-7-carboxylic acid
• CAS NO: 221050-71-1
• Molecular Formula: C10H8N2O2
• Molecular Weight: 188.185
• Product Categories: AMINOACID
• Mol File: 221050-71-1.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 435.8°C at 760 mmHg
• Flash Point: 217.3°C
• Appearance: /
• Density: 1.43g/cm³
• Vapor Pressure: 2.3E-08mmHg at 25°C
• Refractive Index: 1.745
• CAS DataBase Reference: 7-Isoquinolinecarboxylicacid,1-amino-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Isoquinolinecarboxylicacid,1-amino-(9CI)(221050-71-1)
• EPA Substance Registry System: 7-Isoquinolinecarboxylicacid,1-amino-(9CI)(221050-71-1)

Safety Data

• Hazardous Substances Data: 221050-71-1(Hazardous Substances Data)

Usage

Description

7-Isoquinolinecarboxylicacid,1-amino-(9CI), also known as quinolinic acid, is a chemical compound with the chemical formula C10H8N2O2. It is an amino acid derivative of isoquinolinecarboxylic acid and serves as a metabolite in the tryptophan pathway, playing a crucial role in the synthesis of NAD+ in organisms. 7-Isoquinolinecarboxylicacid,1-amino-(9CI) has garnered interest due to its potential neurotoxic effects in neurodegenerative diseases such as Alzheimer's and Parkinson's, as well as its potential applications in the treatment of cancer, inflammation, and infectious diseases. Its wide range of biological activities positions it as a significant compound in both medical research and therapeutic development.

Uses

Used in Pharmaceutical Research and Development:
7-Isoquinolinecarboxylicacid,1-amino-(9CI) is utilized as a key compound in the development of pharmaceuticals targeting neurodegenerative diseases. Its involvement in the tryptophan pathway and its neurotoxic effects make it a valuable subject for research into the underlying mechanisms of diseases like Alzheimer's and Parkinson's.
Used in Cancer Treatment Research:
In the field of oncology, 7-Isoquinolinecarboxylicacid,1-amino-(9CI) is explored as a potential therapeutic agent. Its role in the metabolism and its biological activities suggest that it could be instrumental in developing treatments for various types of cancer.
Used in Inflammation and Infectious Disease Treatments:
7-Isoquinolinecarboxylicacid,1-amino-(9CI) is also considered for its potential applications in anti-inflammatory and antimicrobial drugs. Its ability to modulate immune responses and impact disease progression makes it a candidate for treatments addressing inflammation and infectious diseases.
Used in Biochemical and Metabolic Studies:
In the academic and research sectors, 7-Isoquinolinecarboxylicacid,1-amino-(9CI) serves as an important tool in biochemical and metabolic studies. Its role in the tryptophan pathway and NAD+ synthesis provides insights into fundamental biological processes and may contribute to a better understanding of various metabolic disorders.

InChI:InChI=1/C10H8N2O2/c11-9-8-5-7(10(13)14)2-1-6(8)3-4-12-9/h1-5H,(H2,11,12)(H,13,14)

Relevant articles and documents

1-amino-7-isoquinoline derivatives as serine protease inhibitors

The invention relates to serine protease inhibitor compounds of fornula (I) where R1is hydrogen, halo, cyano, nitro or hydroxyl, amino, alkoxy, alkyl amminoalkyl, hydroxyalkyl, thiol, alkylthio, aminosulphonyl alkoxyalkyl, alkoxycarbonyl, acyloxymethoxycabonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl, cycloalkyl, amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, alkylsulphonamido, alkylaminosulphonyl, haloalkoxy and haloalkyl; R2is hydrogen, halo, methyl amino, hydroxy, or oxo; and R is X—X—Y(R7)—L—Lp(D)n; wheren each X independently is a C, N, O or S atom or a CO, CR1, C(R1)2or NR1group, at least one X being C, CO, CR1or a C(R1)2group; Y (the α-atom) is a nitrogen atom or a CR1group or Y and L taken together form a cyclic group; R7is a lipophilic group selected from alkyl, alkenyl, mono- or bi-cycloalkyl, aryl, heteroaryl, mono- or bicycloalkylalkyl, mono- or bicycloalkylakenyl, aralkyl, heteroaryl-alkyl, arylalkenyl, heteroarylalkenyl all optionally substituted by a group R1; L is an organic linker group containing 1 to 5 backbone atoms selected from C, N, O and S, or a branched alkyl or cyclic group; Lp is a lipophilic organic group selected from alkyl, heterocyclic, alkenyl, alkaryl cycloalkyl, polycycloalkyl, cycloalkenyl, aryl, aralkyl or haloalkyl group or a combination of two or more such groups optionally substituted by one or more of oxa, thia, aza or R1groups; D is a hydrogen bond donor group; and n is 0, 1 or 2 and salts thereof.